Trial Profile
An Open Label, Single-Dose, Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2015
Price :
$35
*
At a glance
- Drugs Gemigliptin (Primary)
- Indications Acute kidney injury; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 17 Apr 2015 New trial record